Works by Shpilberg, Ofer

Results: 99
    1

    The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease.

    Published in:
    Cancers, 2020, v. 12, n. 11, p. 3240, doi. 10.3390/cancers12113240
    By:
    • Weissman, Ran;
    • Diamond, Eli L.;
    • Haroche, Julien;
    • Pillar, Nir;
    • Shapira, Guy;
    • Durham, Benjamin H.;
    • Buthorn, Justin;
    • Cohen, Fleur;
    • Ki, Michelle;
    • Stemer, Galia;
    • Ulaner, Gary A.;
    • Amoura, Zahir;
    • Emile, Jean-François;
    • Mazor, Roei D.;
    • Shomron, Noam;
    • Abdel-Wahab, Omar I.;
    • Shpilberg, Ofer;
    • Hershkovitz-Rokah, Oshrat
    Publication type:
    Article
    2
    3
    4

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
    By:
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • White, Darrell;
    • Moreau, Philippe;
    • Weisel, Katja;
    • San-Miguel, Jesus;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Špička, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Mateos, Maria-Victoria;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Spencer, Andrew;
    • Oakervee, Heather;
    • Orlowski, Robert Z.;
    • Taniwaki, Masafumi;
    • Röllig, Christoph
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 3, p. 243, doi. 10.1002/ajh.23622
    By:
    • Paul, Mical;
    • Ram, Ron;
    • Kugler, Eitan;
    • Farbman, Laura;
    • Peck, Anat;
    • Leibovici, Leonard;
    • Lahav, Meir;
    • Yeshurun, Moshe;
    • Shpilberg, Ofer;
    • Herscovici, Corina;
    • Wolach, Ofir;
    • Itchaki, Gilad;
    • Bar-Natan, Michal;
    • Vidal, Liat;
    • Gafter-Gvili, Anat;
    • Raanani, Pia
    Publication type:
    Article
    27
    28
    29
    30
    31
    32

    Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
    By:
    • Dimopoulos, Meletios A.;
    • Weisel, Katja;
    • Lonial, Sagar;
    • White, Darrell;
    • Moreau, Philippe;
    • Mateos, Maria-Victoria;
    • San-Miguel, Jesus;
    • Anderson, Kenneth C.;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Spicka, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Ganetsky, Alex;
    • Jou, Ying-Ming;
    • McKiver, Mihaela Popa;
    • Singhal, Anil K.
    Publication type:
    Article
    33

    Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.155
    By:
    • Lonial, Sagar;
    • Dimopoulos, Meletios;
    • Weisel, Katja;
    • White, Darrell;
    • Moreau, Philippe;
    • Mateos, Maria-Victoria;
    • San Miguel, Jesus;
    • Anderson, Kenneth;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Spicka, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Shelat, Suresh;
    • Sy, Oumar;
    • Singhal, Anil;
    • Richardson, Paul
    Publication type:
    Article
    34
    35
    36
    37
    38

    Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.

    Published in:
    British Journal of Haematology, 2024, v. 205, n. 1, p. 127, doi. 10.1111/bjh.19462
    By:
    • Friedman, Joshua S.;
    • Durham, Benjamin H.;
    • Reiner, Anne S.;
    • Yabe, Mariko;
    • Petrova‐Drus, Kseniya;
    • Dogan, Ahmet;
    • Pulitzer, Melissa;
    • Busam, Klaus J.;
    • Francis, Jasmine H.;
    • Rampal, Raajit K.;
    • Ulaner, Gary A.;
    • Reddy, Ryan;
    • Yeh, Randy;
    • Hatzoglou, Vaios;
    • Lacouture, Mario E.;
    • Rotemberg, Veronica;
    • Mazor, Roei D.;
    • Hershkovitz‐Rokah, Oshrat;
    • Shpilberg, Ofer;
    • Goyal, Gaurav
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
    By:
    • Delforge, Michel;
    • Terpos, Evangelos;
    • Richardson, Paul G.;
    • Shpilberg, Ofer;
    • Khuageva, Nuriet K.;
    • Schlag, Rudolf;
    • Dimopoulos, Meletios A.;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Petrucci, Maria T.;
    • Samoilova, Olga S.;
    • Mateos, Maria-Victoria;
    • Magen-Nativ, Hila;
    • Goldschmidt, Hartmut;
    • Esseltine, Dixie-Lee;
    • Ricci, Deborah S.;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • van de Velde, Helgi
    Publication type:
    Article
    50

    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
    By:
    • Dimopoulos, Meletios A.;
    • Mateos, Maria-Victoria;
    • Richardson, Paul G.;
    • Schlag, Rudolf;
    • Khuageva, Nuriet K.;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Palumbo, Antonio;
    • Wu, Ka Lung;
    • Esseltine, Dixie-Lee;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • Van De Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article